Navigation Links
Alba Therapeutics Announces the Enrollment and Randomization of the First Patient in the Phase IIb Clinical Trial for Larazotide Acetate (AT-1001) for the Treatment of Active Celiac Disease
Date:5/16/2008

BALTIMORE, May 16 /PRNewswire/ -- Alba Therapeutics Corporation announced today that it has enrolled and randomized its first patient in a twelve-week Phase IIb trial with oral larazotide acetate, an inhibitor of intestinal barrier dysfunction, for the treatment of patients with active celiac disease (CD). The global multi-center, randomized, double-blind, placebo-controlled study will evaluate the clinical and histological efficacy, safety and tolerability of larazotide acetate in 106 active CD subjects adhering to a gluten-free diet, while also testing components of a celiac disease activity rating index, a new patient reported outcomes instrument. "This is Alba's sixth human trial with larazotide acetate and highlights our efforts to improve the treatment of celiac disease and help the celiac community by raising the awareness of this important and neglected disease," stated Dr. Francisco Leon, Head of Clinical Research and Development at Alba. "Alba is committed to studying new treatment options for patients with celiac disease. By conducting this important pioneering clinical study we believe we can learn more about celiac disease and provide insights for physicians and celiac patients," stated Bruce Peacock, CEO of Alba. For more information about Alba's clinical trials, please visit the http://www.clinicaltrials.gov web site and search for Alba Therapeutics.

About Celiac Disease

Celiac disease is a lifelong T-cell mediated auto-immune disorder, which occurs in individuals who are genetically susceptible and is characterized by small intestinal inflammation, injury and intolerance to gluten. CD is a growing public health concern, affecting approximately 3 million people in the United States and over 6.5 million people worldwide. People with CD cannot tolerate gluten proteins and have an inflammatory response to the gluten in wheat, barley and rye. This results in varying symptoms su
'/>"/>

SOURCE Alba Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results
2. Cell Therapeutics, Inc. (CTI) to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
3. Nile Therapeutics Reports 2008 First Quarter Financial Results
4. Fate Therapeutics Taps Successful Biotech CEOs Paul Grayson and John Mendlein for Leadership Team
5. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Nile Therapeutics to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
9. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
10. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
11. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... San Francisco, CA (PRWEB) August 20, 2014 ... Medicine Conference is being held on October 29-30 ... fresh perspectives from industry, academic and government researchers and ... remaining in the space. , In the twelve ... than one hundred therapies have been introduced with pharmacogenetic ...
(Date:8/20/2014)... WriteResult®, a leading provider of Electronic Patient Outcome ... myPROpad™ ePRO tablet with the addition of a touchscreen ... widely used and well-respected Patient Reported Outcome (PRO) instruments ... used during clinical trials and in other health care ... to demonstrate Health-Related Quality of Life outcomes (HRQoL) resulting ...
(Date:8/19/2014)... , Aug. 19, 2014 Research and Markets ... Supplies - Global Strategic Business Report" report to their offering. ... and Tissue Culture Supplies in US$ Thousands by the following Product ... comprehensive analytics for the US, Canada , ... Asia-Pacific , and Latin America . Annual ...
(Date:8/19/2014)... 2014 Robin Williams’ passing is a ... on an individual. Symptoms range from slowness of ... swallowing and severe depression. Parkinson’s disease progressively gets ... dopamine producing neurons of the brain. As these ... slowly and progressively gets worse, they look for options. ...
Breaking Biology Technology:6th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2EQ-5D™ Assessment Now Available for iPad 2Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3
... German . , The concept of confinement ... most famous example is that of quarks which bind together ... Helmholtz-Zentrum Berlin together with an international team of scientists report ... of confinement phenomenon observed in a condensed matter system. ...
... , DURHAM, N.C., Nov. 27 Cromoz Inc., located ... drug delivery system in Hyderabad, India. The water-soluble carbon nanotubes, ... conjugation with cancer drugs, was developed in partnership with the ... as a drug delivery vehicle with the ability to target ...
... ... helping bring complete automation to packaging quality assurance one step closer for ... by Sepha for use with blister packs and it has ... and Zydus-Cadilla to address quality assurance and productivity improvements on the packaging ...
Cached Biology Technology:Spinons -- confined like quarks 2North Carolina Based Cromoz Inc. Launches Carbon Nanotechnology for Target Drug Delivery System in Cancer Treatment in Hyderabad, India 2Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 2Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 3
(Date:8/20/2014)... 20, 2014  The second annual Biometrics UnPlugged ... Tampa, Florida on September 15, ... Rahman, Director, Technology and Strategy at Samsung, and Philippe ... theme of this year,s event is Mobility at ... "Biometrics UnPlugged: Mobility at the Crossroads of ...
(Date:8/19/2014)... Ecological Research and Network-Level Science, , Imagine if we ... of ecosystems was responding to global changes in real ... it coupled multiple decades of information about ecological responses ... from dozens of different ecosystem types. , In ... Research (LTER) Network, which will soon celebrate its 35th ...
(Date:8/19/2014)... a biomarker strongly associated with basal-like breast cancer, ... many types of chemotherapy. The biomarker, a protein ... therapeutics designed to treat this often deadly cancer. ... The Cancer Genome Atlas, molecular biologists Curt M. ... and bioinformatics techniques to detect patterns of gene ...
Breaking Biology News(10 mins):Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2This week from AGU: Long-term ecological research, predicting cholera outbreaks 2Biomarker in an aggressive breast cancer is identified 2Biomarker in an aggressive breast cancer is identified 3
... WI, October 21, 2010 Researchers at the University of ... Florida Water Management District have published a report regarding the ... report can be found in the September-October 2010 Journal ... Agronomy, the Crop Science Society of America, and the Soil ...
... How do humans and their environment interact, and how ... adapt to a planet undergoing far-reaching climate and other ... the National Science Foundation (NSF) has awarded 14 grants ... study coupled natural and human systems. Research conducted ...
... NY, October 21, 2010Antigene therapy is a promising new ... light energy to a target gene shutting down its ... in Oligonucleotides , a peer-reviewed journal published by ... possibilities and challenges for the clinical application of this ...
Cached Biology News:Everglades show improvement in water quality 2NSF awards grants for research on coupled natural and human systems 2NSF awards grants for research on coupled natural and human systems 3NSF awards grants for research on coupled natural and human systems 4NSF awards grants for research on coupled natural and human systems 5NSF awards grants for research on coupled natural and human systems 6Promising new 'antigene' therapy 2
... personal-sized Thermal Cycler is the ideal instrument for ... range of PCR applications. Get Applied ... Save lab space without sacrificing results. ... Industry-Standard PCR Technology You Can Afford ...
... The genus Salmonella is a member of ... Gram-negative bacilli that are facultative and flagellated (motile). ... flagellar antigen (phase 1 & 2), the "O" ... and the "Vi" or capsular antigen (referred to ...
... pyruvate, 50 mg/L streptomycin sulfate, 100 mg/L ... and magnesium chloride. The use of a ... is generally attributed to early workers in ... a solution of inorganic salts designed to ...
... a dramatic breakthrough in accurate, small-volume bulk dispensing. ... the micro 1 has unique advantages not found ... 1 never needs re-calibration as do other 1mL ... an LCD Display , Graphical Row Selection , ...
Biology Products: